Opportunity Information: Apply for RFA DK 27 147
This funding opportunity, titled "Single Source for Continuation of the Integrated Islet Distribution Program (IIDP) U24 (Clinical Trial Not Allowed)," is a National Institutes of Health (NIH) Notice of Funding Opportunity (NOFO) issued by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). It is set up as a single-source cooperative agreement competition, meaning NIH intends to invite and consider an application only from the specific currently supported program leadership rather than opening the competition broadly to multiple institutions. Even though it is single-source, the application will still go through NIH’s standard peer-review process, and funding will be made only if the proposal is judged scientifically and programmatically strong.
The core purpose of the award is to renew and continue the Integrated Islet Distribution Program, which supports diabetes research by ensuring that investigators can access high-quality human islets. Human islets are a foundational resource for studying human islet cell biology and for developing and testing new ideas relevant to diabetes prevention and treatment. The IIDP’s practical role is to facilitate the preparation and distribution of human islets to the broader biomedical research community by building and maintaining partnerships with qualified islet isolation facilities. In other words, the program functions as a coordinated national resource: it works with specialized centers that can isolate islets, and then it manages the logistics and systems needed to distribute those islets to researchers who rely on them for laboratory studies.
NIDDK states its intent to make a single cooperative agreement award to the Beckman Research Institute/City of Hope, which currently holds the IIDP award. The continuation is meant to maintain support for the program’s ongoing mission and infrastructure rather than to launch an entirely new initiative. The activity code is U24, which generally supports resource-related or service-oriented research infrastructure under a cooperative agreement structure, implying substantial NIH involvement in program oversight and coordination compared with a standard grant.
This NOFO is tied to the Special Diabetes Program, a congressionally funded effort that supports research on type 1 diabetes and its complications, including large-scale collaborative research activities and clinical trial networks. While the broader Special Diabetes Program can include clinical trials, this specific NOFO explicitly states "Clinical Trial Not Allowed," indicating that the funded activities under this award are not intended to support clinical trial work. The emphasis here is on sustaining a shared research resource that enables many downstream studies across the diabetes research landscape.
Eligibility is tightly restricted. Only the Project Director/Principal Investigator(s) associated with the award issued under RFA-DK-20-509 to Beckman Research Institute/City of Hope may apply. This effectively limits applications to the existing leadership team connected to the current IIDP award, reflecting NIH’s intent to continue the established program rather than recompete it among new applicants. The opportunity also contains strict limits on foreign involvement: non-U.S. (foreign) organizations are not eligible to apply, non-U.S. components of U.S. organizations are not eligible, and foreign components (as defined by NIH Grants Policy) are not allowed.
Key administrative details include the funding opportunity number RFA-DK-27-147, funding instrument type "Cooperative Agreement," and an activity category focused on health (CFDA 93.847). NIH expects to make one award, with an award ceiling of $2,200,000. The opportunity was created on 2026-05-20, and the original closing date is 2026-09-30. Overall, the announcement is designed to ensure continuity of a nationally important diabetes research resource by renewing the existing IIDP operation at City of Hope under NIH cooperative agreement oversight.Apply for RFA DK 27 147
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Single Source for Continuation of the Integrated Islet Distribution Program U24 (Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.847.
- This funding opportunity was created on 2026-05-20.
- Applicants must submit their applications by 2026-09-30. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $2,200,000.00 in funding.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the title of this funding opportunity?
The opportunity is titled "Single Source for Continuation of the Integrated Islet Distribution Program (IIDP) U24 (Clinical Trial Not Allowed)."
Which agency and institute are offering this opportunity?
This is a National Institutes of Health (NIH) Notice of Funding Opportunity (NOFO) issued by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
What is the funding opportunity number (NOFO number)?
The funding opportunity number is RFA-DK-27-147.
What type of award is being offered?
The funding instrument is a Cooperative Agreement.
What does the activity code U24 mean in this context?
The activity code is U24, which generally supports resource-related or service-oriented research infrastructure under a cooperative agreement structure. In practical terms, it indicates substantial NIH involvement in oversight and coordination compared with a standard grant mechanism.
What is the purpose of this award?
The purpose is to renew and continue the Integrated Islet Distribution Program (IIDP), which supports diabetes research by ensuring investigators can access high-quality human islets and by sustaining the infrastructure and partnerships needed to prepare and distribute human islets to the research community.
What is the Integrated Islet Distribution Program (IIDP)?
The IIDP is a coordinated national resource that facilitates the preparation and distribution of human islets to the broader biomedical research community by building and maintaining partnerships with qualified islet isolation facilities and managing the systems and logistics needed to supply researchers.
Why are human islets important to diabetes research?
Human islets are described as a foundational resource for studying human islet cell biology and for developing and testing new ideas relevant to diabetes prevention and treatment. The IIDP exists to make these high-quality islets accessible to investigators.
Is this a new program or a continuation?
This NOFO is intended as a continuation (renewal) of the existing IIDP, with the goal of maintaining support for the program's ongoing mission and infrastructure rather than launching an entirely new initiative.
Is this opportunity open to multiple applicants?
No. This is described as a single-source cooperative agreement competition. NIH intends to invite and consider an application only from the currently supported program leadership rather than opening the competition broadly to multiple institutions.
Who is NIH intending to fund under this announcement?
NIDDK states its intent to make a single cooperative agreement award to the Beckman Research Institute/City of Hope, which currently holds the IIDP award.
Who is eligible to apply?
Eligibility is tightly restricted. Only the Project Director/Principal Investigator(s) associated with the award issued under RFA-DK-20-509 to Beckman Research Institute/City of Hope may apply.
Are foreign organizations eligible to apply?
No. Non-U.S. (foreign) organizations are not eligible to apply under this opportunity.
Are non-U.S. components of U.S. organizations eligible?
No. Non-U.S. components of U.S. organizations are not eligible.
Are foreign components allowed in the project?
No. Foreign components (as defined by NIH Grants Policy) are not allowed under this opportunity.
Will the application still be peer reviewed even though it is single-source?
Yes. Even though NIH intends to consider only the specific currently supported leadership, the application will still go through NIH's standard peer-review process, and funding will be made only if the proposal is judged scientifically and programmatically strong.
How many awards does NIH expect to make?
NIH expects to make one award.
What is the maximum award amount (ceiling)?
The award ceiling listed for this opportunity is $2,200,000.
What is the main focus area or category for this funding?
The activity category is focused on health, and the opportunity is listed under CFDA 93.847.
Is this opportunity connected to the Special Diabetes Program?
Yes. This NOFO is tied to the Special Diabetes Program, a congressionally funded effort supporting research on type 1 diabetes and its complications, including large-scale collaborative research activities and clinical trial networks.
Are clinical trials allowed under this award?
No. The NOFO explicitly states "Clinical Trial Not Allowed," meaning the funded activities under this award are not intended to support clinical trial work.
If clinical trials are not allowed, what kind of work is supported?
Based on the description provided, the emphasis is on sustaining a shared research resource and its operations, partnerships, and distribution infrastructure so that many downstream diabetes studies can be enabled by access to high-quality human islets.
What role does NIH play in a cooperative agreement like this?
The cooperative agreement structure implies substantial NIH involvement in program oversight and coordination compared with a standard grant, consistent with maintaining and coordinating a national research resource.
When was this funding opportunity created?
The opportunity was created on 2026-05-20.
What is the original closing date?
The original closing date is 2026-09-30.
What is the overall goal of issuing this NOFO?
The overall goal is to ensure continuity of a nationally important diabetes research resource by renewing the existing IIDP operation at City of Hope under NIH cooperative agreement oversight.
Browse more opportunities from the same category: Health
Next opportunity: Rural Postsecondary and Economic Development Grant Program
Previous opportunity: Alumni Engagement Innovation Fund (AEIF) 2026
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DK 27 147
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DK 27 147) also looked into and applied for these:
| Funding Opportunity |
|---|
| HEAL INITIATIVE: INTERACT Data Coordination and Integration Center (U24 Clinical Trial Not Allowed) Apply for RFA AR 27 002 Funding Number: RFA AR 27 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NCI Community Oncology Research Program (NCORP) Community Sites (UG1 Clinical Trial Not Allowed) Apply for RFA CA 27 007 Funding Number: RFA CA 27 007 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NCI Community Oncology Research Program (NCORP) Research Bases (UG1 Clinical Trial Required) Apply for RFA CA 27 006 Funding Number: RFA CA 27 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Avant Garde/Avenir Awards for Investigators Conducting High Risk/High Reward Research on HIV and Substance Use (or Substance Use Disorders) (DP1 Clinical Trial Optional) Apply for PAR 27 026 Funding Number: PAR 27 026 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NCI Community Oncology Research Program (NCORP) Academic Community Sites (UG1 Clinical Trials Not Allowed) Apply for RFA CA 27 008 Funding Number: RFA CA 27 008 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Maximizing the Scientific Value of Data Generated by the Environmental influences on Child Health Outcomes (ECHO) Program: Dissertation Grant (R36 - Clinical Trial Not Allowed) Apply for RFA OD 27 006 Funding Number: RFA OD 27 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Maximizing the Scientific Value of Data Generated by the Environmental Influences on Child Health Outcomes (ECHO) Program: Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (F32) Apply for RFA OD 27 008 Funding Number: RFA OD 27 008 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical Trial Required) Apply for RFA MH 27 140 Funding Number: RFA MH 27 140 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) Apply for RFA NS 27 007 Funding Number: RFA NS 27 007 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Single Source: Cardiothoracic Surgical Trials Network (CTSN) Data Coordinating Center (U01 Clinical Trial Required) Apply for RFA HL 27 002 Funding Number: RFA HL 27 002 Agency: National Institutes of Health Category: Health Funding Amount: $8,000,000 |
| Advancing Research on Empirically-Supported Interventions for Older Adults Living with Serious Mental Illness (SMI) (R01 Clinical Trial Optional) Apply for RFA MH 27 180 Funding Number: RFA MH 27 180 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed) Apply for RFA RM 27 014 Funding Number: RFA RM 27 014 Agency: National Institutes of Health Category: Health Funding Amount: $2,000,000 |
| Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed) Apply for RFA RM 27 015 Funding Number: RFA RM 27 015 Agency: National Institutes of Health Category: Health Funding Amount: $575,000 |
| PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional) Apply for RFA RM 27 012 Funding Number: RFA RM 27 012 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| GREGoRi Data Coordination and Outreach Center (U01, Clinical Trials Not Allowed) Apply for RFA HG 27 011 Funding Number: RFA HG 27 011 Agency: National Institutes of Health Category: Health Funding Amount: $1,250,000 |
| Limited Competition for the Adolescent Brain Cognitive Development -Extended (ABCD-E) Study Renewal - Data Analysis, Informatics and Resource Center, and Coordinating Center (U24 Clinical Trial Not Allowed) Apply for RFA DA 27 003 Funding Number: RFA DA 27 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| GREGoRi Technology Integration Center (U01, Clinical Trials Optional) Apply for RFA HG 27 012 Funding Number: RFA HG 27 012 Agency: National Institutes of Health Category: Health Funding Amount: $2,250,000 |
| GREGoRi Innovation Projects (U01 Clinical Trial Optional) Apply for RFA HG 27 013 Funding Number: RFA HG 27 013 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Renewal of the Clinician-Scientists Transdisciplinary Aging Research (Clin-STAR) Coordinating Center (U24 Clinical Trial Not Allowed) Apply for RFA AG 27 007 Funding Number: RFA AG 27 007 Agency: National Institutes of Health Category: Health Funding Amount: $1,500,000 |
| Limited Competition: Superfund Hazardous Substance Research and Training Program (P42 Clinical Trial Optional) Apply for RFA ES 27 004 Funding Number: RFA ES 27 004 Agency: National Institutes of Health Category: Health Funding Amount: $1,750,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DK 27 147", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.